



Advancing detection and response capacities for emerging and re-emerging pathogens in Africa

Jean B Nachege*, Sabin Nsanzimana*, Angeli Rawat, Lindsay A Wilson, Philip J Rosenthal, Mark J Siedner, Jay K Varma, Peter H Kilmarx, Leon Mutesa, Marcel Tanner, Agnes Binagwaho, Jamie Forrest, Placide Mbala-Kingebeni, Jean-Jacques Muyembe-Tamfum, Francine Ntoumi, Alimuddin Zumla, Tulio de Oliveira, Edward J Mills

Recurrent disease outbreaks caused by a range of emerging and resurging pathogens over the past decade reveal major gaps in public health preparedness, detection, and response systems in Africa. Underlying causes of recurrent disease outbreaks include inadequacies in the detection of new infectious disease outbreaks in the community, in rapid pathogen identification, and in proactive surveillance systems. In sub-Saharan Africa, where 70% of zoonotic outbreaks occur, there remains the perennial risk of outbreaks of new or re-emerging pathogens for which no vaccines or treatments are available. As the Ebola virus disease, COVID-19, and mpox (formerly known as monkeypox) outbreaks highlight, a major paradigm shift is required to establish an effective infrastructure and common frameworks for preparedness and to prompt national and regional public health responses to mitigate the effects of future pandemics in Africa.

The colliding epidemics of Ebola virus disease, COVID-19, measles, and mpox (formerly known as monkeypox) outbreaks¹ have highlighted inadequacies of current infrastructure and capacities for epidemic preparedness in Africa. The inequities of resource allocation and vaccine distribution during the COVID-19 pandemic have emphasised the need for Africa to advance its detection and response capacities.² Capacity building in public health preparedness requires training and retaining public health experts. Building local ownership of health systems will help to improve the resilience of countries' health systems during times of crisis, while contributing to improved health globally by reducing the risk of regional and global disease spread. National governments need to provide public health officials with sufficient legal authority with continuous and stable funding by leveraging the commendable efforts of the Africa Centres for Disease Control and Prevention (Africa CDC), to improve response to emerging and re-emerging pathogens in Africa.³

During the COVID-19 pandemic, global supply chains were severely disrupted. Contentious trade agreements and hoarding of supplies by resource-rich governments exacerbated shortages of essential items, especially in low-income and middle-income countries. National, regional, and global supply chains should be established to ensure equitable access to crucial supplies between and during crises. Supply chains should be decentralised to promote fair allocation of resources and maintain essential health system functions. Contracts should be established with suppliers of key commodities to procure essential supplies in a timely manner.² Finally, local, and regional manufacturing and distribution capacities should be strengthened to improve production, as access to raw materials and transportation networks might be compromised during emergencies. During the COVID-19 pandemic, many factories in Africa switched to the making of essential supplies, and new partnerships were developed to improve manufacturing capacities.

Manufacturers should be encouraged to increase their production capacity to respond to global health demands. National governments should establish partnerships with the private sector to build on the lessons learned from the Ebola virus disease and COVID-19 outbreaks.²

The time between the discovery of a new or re-emerging pathogen and its spread into a localised epidemic is a crucial window to prevent pandemics. Strong surveillance systems are essential for early detection, and the creation of data science hubs across Africa can support these efforts.⁴ These systems will require implementing public health laws for mandatory data reporting in electronic formats, and a stable information technology infrastructure with strong cybersecurity and confidentiality systems.⁴ Government agencies should cooperate to establish data science hubs staffed by scientists who will compile and analyse data in real time, with high levels of completeness and accuracy. To support these hubs, Africa CDC, in collaboration with governments, will need to expand its multidisciplinary teams of disease detectives. High-risk zones might be identified with existing knowledge of disease burden, local epidemiology, and analyses performed at the hubs. Moving forward with a One Health approach, networks of local and regional multidisciplinary teams should consist of experts in human, animal, and environmental health to detect emerging pathogens with outbreak and pandemic potential.⁵ Field teams can report community-level data to the regional network in real time to support population-level analyses conducted at data science hubs.⁶

Access to diagnostics is essential to ensure that surveillance data are accurate. During the COVID-19 response, inadequate diagnostic capacity meant that health systems could neither detect nor predict true case numbers. Even when diagnostic tests are available, laboratories are often centralised and use tests that require advanced training, expertise, sample transportation processes, and infrastructure, leading to delayed results, especially in remote areas. There is a crucial need to

Lancet Infect Dis 2022

Published Online
December 20, 2022
[https://doi.org/10.1016/S1473-3099\(22\)00723-X](https://doi.org/10.1016/S1473-3099(22)00723-X)

*Contributed equally

Department of Epidemiology (Prof J B Nachege MD PhD) and Department of Infectious Diseases and Microbiology (Prof J B Nachege), University of Pittsburgh School of Public Health, Pittsburgh, PA, USA; Department of Medicine, Division of Infectious Diseases (Prof J B Nachege), School for Data Science and Computational Thinking (Prof T de Oliveira PhD), and Centre for Epidemic Response and Innovation (Prof T de Oliveira), Faculty of Science and Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa; Department of Epidemiology (Prof J B Nachege) and Department of International Health (Prof J B Nachege), Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; University Teaching Hospital, Butare, Rwanda (S Nsanzimana PhD); University of Global Health Equity, Kigali, Rwanda (S Nsanzimana, Prof A Binagwaho PhD); Department of Health Research Methods, Evidence and Impact, Faculty of Health Sciences, McMaster University, Hamilton, ON, Canada (A Rawat PhD, Prof E J Mills PhD); School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada (A Rawat); Platform Life Sciences, Vancouver, BC, Canada (L A Wilson MSc, J Forrest PhD, Prof E J Mills); Department of Real World and Advanced Analytics, Vancouver, Cytel, Vancouver, BC, Canada (L A Wilson, J Forrest); Department of Medicine, Division of Infectious Diseases, University of California San Francisco, San Francisco, CA, USA

(Prof P J Rosenthal MD); Department of Medicine, Harvard Medical School and Massachusetts General Hospital, Boston, MA, USA (M J Siedner MD); Faculty of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda (M J Siedner); Department of Population Health Sciences, Weill Cornell Medicine, NY, USA (Prof J K Varma MD); Fogarty International Center, National Institutes of Health, Bethesda, MD, USA (P H Kilmarx MD); Center for Human Genetics, University of Rwanda, Kigali, Rwanda (L Mutesa PhD); Swiss Tropical and Public Health Institute, University of Basel, Basel, Switzerland (Prof M Tanner PhD); National Institute for Bio-Medical Research, Kinshasa, Democratic Republic of the Congo (Prof P Mbala-Kingebeni PhD, Prof J-J Muyembe-Tamfum PhD) University of Kinshasa School of Medicine, Kinshasa, Democratic Republic of the Congo (Prof P Mbala-Kingebeni, Prof J-J Muyembe-Tamfum); Fondation Congolaise pour la Recherche Médicale, Brazzaville, Republic of the Congo (Prof F Ntoumi PhD); Institute for Tropical Medicine, University of Tübingen, Tübingen, Germany (Prof F Ntoumi); Division of Infection and Immunity, Centre for Clinical Microbiology, University College London, London, UK (Prof A Zumla PhD); NIHR Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, UK (Prof A Zumla)

Correspondence to: Prof Jean B Nachega, Department of Epidemiology and Department of Infectious Diseases and Microbiology, University of Pittsburgh School of Public Health, Pittsburgh, PA 15261, USA
jbn16@pitt.edu

Panel: Response to emerging and re-emerging pathogens in Africa

Area of focus: strengthening public health preparedness and coordination of regional or sub-Saharan Africa response Gaps

- Few public health experts with training in emerging and re-emerging pathogens.

Recommendations and solutions

- Governments and academics to expand and adapt public health training programmes for pandemic preparedness and response-focused research capacity building as well as skills transfer.²
- Governments to increase public health schools and adapt their curricula for better control of current and future pandemic threats.

Real-world examples

- The Africa Centres for Disease Control and Prevention (Africa CDC) leveraging the African Field Epidemiology Network (AFENET), which was established in 2005 as a non-profit organisation and networking alliance of African Field Epidemiology and Laboratory Training Programs, and other applied epidemiology training programmes. The organisation has its headquarters in Kampala, Uganda, with seven AFENET regional hubs.
- Genomics Africa Fellowship 2022 programme providing a support system for upskilling the scientific workforce, with around 100 fellows from more than 12 countries being welcomed by the Centre for Epidemic Response and Innovation in Cape Town, South Africa.

Area of focus: building local supply chains for essential health supplies and addressing vaccine equity through global cooperation

Gaps

- Lack of manufacturing infrastructure for local production of public health supplies (eg, personal protective equipment [PPE], masks, gloves, sanitisers, diagnostics, therapeutics, and vaccines).
- Disruption in global supply chains of PPE, diagnostic and testing supplies (eg, reagents, test kits, and sample transportation), therapeutics, and vaccines.

Recommendations and solutions

- Governments and health agencies to strengthen regional and local manufacturing and distribution capacities, and access to raw materials, trade, and transportation networks.²
- Africa CDC in coordination with governments to create prompt supply chain frameworks allowing rapid deployment of urgent medical tools from anywhere within hours.

Real-world examples

- In Kenya, Hela Clothing shifted its manufacturing facility from making men's underwear to making masks. They produced 10 million face masks in April and May, 2021,

90% of which were standard 3-ply surgical masks, with the remaining 10% being reusable fabric masks.

- The mRNA COVID-19 vaccine technology transfer programme, a global initiative that aims to establish sustainable, locally owned mRNA manufacturing capabilities in and for low-income and middle-income countries. The programme is based around a technology transfer hub Afrigen, located in Cape Town, South Africa.

Area of focus: establishing strong, integrated surveillance systems, and data sharing hubs

Gaps

- Weak or non-existent surveillance systems.
- Limited capacity for big data science analysis.

Recommendations and solutions

- Strengthen surveillance system and early warning signs.²
- Establish big data science hubs by Africa CDC or WHO.
- Integrate information systems by Africa CDC or WHO.
- South-south and north-south Africa data sharing⁶ by Centers of Excellence (CoE) or universities.

Real-world examples

- Ongoing coordination between big pathology laboratories, such as those in South Africa, Nigeria, Kenya, Botswana, and Uganda, for performing common pathogen testing and diagnostics. Because of the short turnaround time for these tests, a good network has been established for enhanced integrated surveillance and data sharing.

Area of focus: strengthening diagnostic laboratory capacity and pathogen genomics

Gaps

- Limited diagnostics and laboratory capacity beyond referral centres.
- Limited genomics surveillance capacity.

Recommendations and solutions

- Establish decentralised laboratory services with the use of a mobile laboratory for service, research, and point-of-care diagnostic tools in remote and rural areas to allow for reliable and rapid systems for specimen transport and the return of clinically relevant test results by CoE.
- Develop rapid and safe sample transportation systems within countries and beyond by CoE.
- Multidonor investment in and expansion of existing genomic sequencing facilities.^{7,8}

Real-world examples

- The work of the Africa CDC and WHO in strengthening and expanding genomic capacity in Africa (collaborating centres—such as the African Centre of Excellence for Genomics of Infectious Diseases in Ede, Nigeria—are examples of ongoing efforts to realise this potential).

(Continues on next page)

(Continued from previous page)

Area of focus: developing a robust and real-time clinical trial capacity vaccine infrastructure

Gaps

- Limited funding and capacity to conduct high-quality clinical trials of emerging and re-emerging pathogens during the pandemic response to inform clinical and public health policies.

Recommendations and solutions

- Develop a pre-service and in-service clinical trial training programme focusing on pandemic preparedness by CoEs and universities.
- Secure public and private funding to invest in training of robust and adaptable master trial protocols involving multi-disciplinary teams by CoEs and universities.

Real-world examples

- The successful Ebola virus disease vaccine and therapeutic trials conducted during the 2013–16 Ebola virus disease outbreaks in west Africa and the Democratic Republic of the Congo highlighted what can be achieved in Africa with capacity building, investment, partnerships, and leadership.
- The rapid development of COVID-19 vaccines in a record time of 9 months should be replicated in low-income and middle-income countries following capacity building.
- Real-time adaptive COVID-19 trials (eg, PALM001, TOGETHER trials).^{9,10}

Area of focus: promoting community engagement and commitment to public health, leadership, coordination, and financing

Gaps

- Limited community awareness and engagement.
- Limited global coordination of COVID-19 response.
- Limited financing allocated to COVID-19 response.

Recommendations and solutions

- Involve community health workers and opinion leaders in community awareness campaigns by non-profit organisations.¹¹
- Establish multisectoral collaborations and partnerships, including strong political and finance leadership at national and international levels by governments.

Real-world examples

- In Uganda, community engagement strategy for COVID-19 response launched by the Prime Minister on Oct 20, 2020, required the establishment of a COVID-19 task force in every village to foster trust, manage stigma, and support contact tracing.
- The World Bank's new Fund for Pandemic Prevention, Preparedness and Response is a key initiative in this area of focus, but pledges must be supported with adequate funding.¹²

establish local laboratory networks with robust systems for specimen transport, and for the return of test results via electronic data transmission to public health agencies using modern messaging methods. Recent efforts to leverage existing laboratory infrastructure for COVID-19 (eg, WHO Africa network of polio laboratories or HIV and tuberculosis GeneXpert PCR diagnostic capacity used for COVID-19 testing) at referral and university-level laboratories for decentralisation to community-level government laboratories, were commendable efforts and should be expanded. Furthermore, regional and national laboratories should have the ability to perform genomic sequencing to monitor new outbreaks and variants of concern. This capacity has been crucial throughout the COVID-19 response. The discovery of the omicron variant of SARS-CoV-2 by researchers in Botswana and South Africa in November, 2021, and the rapid sharing of data with international colleagues serve as examples of the global benefits of adequate diagnostic capacity in low-income and middle-income countries.^{7,8}

High-quality clinical trial infrastructure should be strengthened in Africa to provide regionally generalisable data, and ensure that therapeutics and vaccines are evaluated even if a disease is not prevalent in high-income settings. The ability to quickly identify or develop effective vaccines and treatments, including testing products off-label, will lead to more efficient containment

of outbreaks. Multidisciplinary teams should be developed to conduct priority research at short notice during outbreaks. Robust and flexible platform trial methods and adaptive therapeutic trials^{9,10} that were developed during Ebola virus disease outbreaks and the COVID-19 pandemic can be leveraged for new outbreaks and pathogens. Prompt regulatory review during these emergencies can also be adapted to promote greater efficiency in clinical research.

Trust should be developed before, during, and after outbreaks, and should build on honesty, transparent communication, and good governance—both by training public health experts in communicating effectively to counter misinformation and engage communities and their trusted leaders, including health-care workers, ministries of health, and religious and civil society organisations. During the Ebola virus disease response, community engagement and trust were interdependent and promoted safe burial practices, hand washing, and case identification.¹¹ Similarly, during the COVID-19 pandemic, community cooperation was an essential part of containment efforts, bolstered by effective communication and leadership. Public health community advisory boards should be established and include trusted community leaders who can be consulted during health emergencies. Community advisory boards serve as important links between communities and health systems, filling the gaps

in outreach activities and addressing misinformation, while ensuring that interventions are culturally appropriate and locally relevant.¹¹

Strong leadership, partnerships, and cooperation between scientists, clinicians, public health experts, health-care workers, government leaders, and funders are essential for outbreak control. Enhanced frameworks for global public health financing and accountability should be revisited and strengthened, building on the new World Bank Fund for Pandemic Prevention, Preparedness and Response, which promises to bring additional resources, incentivise country investment, and enhance partner coordination.¹² However, in the context of competition for resources, as with the COVID-19 pandemic, national budgets should account for public health preparedness, and African countries should be as self-sufficient as possible, contributing to the local discovery and production of tools needed for responding to health threats.⁵

In summary, the COVID-19 pandemic revealed numerous gaps in global health preparedness and financing, highlighting the need for a paradigm shift towards a surveillance–response approach. Although the COVID-19 pandemic brought innovations, including improved surveillance, diagnostics, contact tracing, vaccine development, and treatments, enabling rapid identification of new virus variants and reduced morbidity and mortality, the benefits of these advances were inequitably distributed, and were limited by insufficient and delayed access in African countries. As a roadmap for African governments, stakeholders, and

public–private health agencies to prepare for future pandemics, we call for: (1) strengthening public health preparedness, regional coordination, and response; (2) building supply chains for essential health supplies, including diagnostics, treatments, and vaccines; (3) establishing strong, integrated surveillance systems and monitoring using real-time data sharing and storage hubs with innovative digital tools; (4) decentralising and strengthening diagnostic laboratory capacity for diagnostics and pathogen genomics; (5) developing a robust clinical trial capacity; and (6) supporting community engagement and trust with a commitment to public health, leadership, coordination, and financing (panel). Finally, these improvements should be linked to well resourced and robust health systems and research networks that are prepared to address new health threats and translate early detection into rapid information sharing with coordinated health system responses in Africa.

Contributors

JBN, SN, AR, and LAW drafted the manuscript. All authors contributed to the writing, revision, and approval of the final version of the manuscript.

Declaration of interests

JBN is supported by the US National Institutes of Health (NIH; grant numbers NIH/FIC 1R25TW011217-01, NIH/FIC 1D43TW010937-01A1, NIH/FIC D43TW011827-01A1, NIH/FIC 1R21TW011706-0, and NIH/NIAID 5U01A1096299-13). FN and AZ are Co-directors of the Pan-African Network on Emerging and Re-Emerging Infections funded by the European and Developing Countries Clinical Trials Partnership (EDCTP) within the EU Horizon 2020 Framework Programme. FN and AZ also acknowledge support from the EDCTP Central Africa Clinical Research Network. AZ is a UK National Institute for Health Research senior investigator, and a Mahathir Science Award and EU-EDCTP Pascoal Mocumbi Prize laureate. J-JM-T is supported by Africa Centre for Disease Control and Prevention and the Bill and Melinda Gates Foundation, and holds NIH grants (NIH/NIAID grant number 75N91019D00024-P00001-759102000025-5). J-JM-T was part of the group that discovered the Ebola virus in 1976, and was awarded Le Prix Christophe Merieux from Institut de France in 2015 and was the recipient of the third Hideyo Noguchi Africa Prize for Medical Research in 2019 from the Japan Government, for his research to confront Ebola and other emerging and re-emerging pathogens, and for his efforts to train legions of disease fighters in Africa. All other authors declare no competing interests. IdO led the team of South African researchers who discovered the omicron variant of SARS-CoV-2 in November, 2021.

Acknowledgments

We thank John L Johnson (Case Western Reserve University, Cleveland, OH, USA), and Joel G Breman (US National Institutes of Health and Fogarty International Center, Bethesda, MD, USA) for critical review and helpful advice. The views and conclusions in this Personal View are those of the authors and do not necessarily represent the views of their institutions.

References

- 1 Nachega JB, Mbala-Kingebeni P, Otshudiema J, Zumla A, Tam-Fum J-JM. The colliding epidemics of COVID-19, Ebola, and measles in the Democratic Republic of the Congo. *Lancet Glob Health* 2020; 8: e991–92.
- 2 Maxmen A. Has COVID taught us anything about pandemic preparedness? *Nature* 2021; 596: 332–35.
- 3 Nkengasong JN, Tessema SK. Africa needs a new public health order to tackle infectious disease threats. *Cell* 2020; 183: 296–300.
- 4 Adepoju P. African coronavirus surveillance network provides early warning for world. *Nat Biotechnol* 2022; 40: 147–48.

Search strategy and selection criteria

MeSH terms in PubMed were used to identify key literature that focuses on “COVID-19” and “health systems” as the priority: (“COVID-19” [MeSH] OR “SARS-CoV-2” [MeSH] OR “COVID-19 Testing” [MeSH] OR “COVID-19 Nucleic Acid Testing” [MeSH] OR “COVID-19 Vaccines” [MeSH] OR “COVID-19 Serological Testing” [MeSH]) OR (“Health Information Systems” [MeSH] OR “Health Systems Agencies” [MeSH] OR “Health Systems Plans” [MeSH] OR “Public Health Systems Research” [MeSH] OR “Delivery of Health Care, Integrated” [MeSH] OR “Delivery of Health Care” [MeSH] OR “Learning Health System” [MeSH] OR “Community Health Planning” [MeSH] OR “Sentinel Surveillance” [MeSH]). Publications were limited to those that focused on Africa and were written in English or French. We performed additional searches for articles in Africa focusing on the following keywords and their related variants: “surveillance”, “capacity building”, “community engagement”, “trust”, “vaccine equity preparedness”, “research capacity”, and “genomic sequencing”. We also conducted a separate search in PubMed to identify key lessons from the Ebola outbreak. Coauthors were requested to provide additional resources from their contexts and experiences.

- 5 Zumla A, Dar O, Kock R, et al. Taking forward a 'One Health' approach for turning the tide against the Middle East respiratory syndrome coronavirus and other zoonotic pathogens with epidemic potential. *Int J Infect Dis* 2016; **47**: 5–9.
- 6 Ntoumi F, Zumla A. Advancing accurate metrics for future pandemic preparedness. *Lancet* 2022; **399**: 1443–45.
- 7 Viana R, Moyo S, Amoako DG, et al. Rapid epidemic expansion of the SARS-CoV-2 omicron variant in southern Africa. *Nature* 2022; **603**: 679–86.
- 8 Petersen E, Ntoumi F, Hui DS, et al. Emergence of new SARS-CoV-2 variant of concern omicron (B.1.1.529) highlights Africa's research capabilities, but exposes major knowledge gaps, inequities of vaccine distribution, inadequacies in global COVID-19 response and control efforts. *Int J Infect Dis* 2022; **114**: 268–72.
- 9 Mulangu S, Dodd LE, Davey RT Jr, et al. A randomized, controlled trial of Ebola virus disease therapeutics. *N Engl J Med* 2019; **381**: 2293–303.
- 10 Reis G, Dos Santos Moreira-Silva EA, Medeiros Silva DC, et al. Effect of early treatment with flvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. *Lancet Glob Health* 2022; **10**: e42–51.
- 11 Barker KM, Ling EJ, Fallah M, et al. Community engagement for health system resilience: evidence from Liberia's Ebola epidemic. *Health Policy Plan* 2020; **35**: 416–23.
- 12 The World Bank. World Bank board approves new fund for Pandemic Prevention, Preparedness and Response (PPR). June 30, 2022. <https://www.worldbank.org/en/news/press-release/2022/06/30/-world-bank-board-approves-new-fund-for-pandemic-prevention-preparedness-and-response-ppr> (accessed Oct 7, 2022).

Copyright © 2022 The Author(s). Published by Elsevier Ltd.